Intrahepatic upregulation of MRTF-A signaling contributes to increased hepatic vascular resistance in cirrhotic rats with portal hypertension - 15/12/17
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 8 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Background |
Portal hypertension in cirrhosis is mediated, in part, by increased intrahepatic resistance, reflecting massive structural changes associated with fibrosis and intrahepatic vasoconstriction. Activation of the Rho/MRTF/SRF signaling pathway is essential for the cellular regulatory network of fibrogenesis. The aim of this study was to investigate MRTF-A-mediated regulation of intrahepatic fibrogenesis in cirrhotic rats.
Methods |
Portal hypertension was induced in rats via an injection of CCl4 oil. Hemodynamic measurements were obtained using a polyethylene PE-50 catheter and pressure transducers. Expression of hepatic fibrogenesis was measured using histological staining. Expression of protein was measured using western blotting.
Results |
Upregulation of MRTF-A protein expression in the livers of rats with CCl4-induced cirrhosis was relevant to intrahepatic resistance and hepatic fibrogenesis in portal hypertensive rats with increased modeling time. Inhibition of MRTF-A by CCG-1423 decelerated hepatic fibrosis, decreased intrahepatic resistance and portal pressure, and alleviated portal hypertension.
Conclusion |
Increased intrahepatic resistance in rats with CCl4-induced portal hypertension is associated with an upregulation of MRTF-A signaling. Inhibition of this pathway in the liver can decrease hepatic fibrosis and intrahepatic resistance, as well as reduce portal pressure in cirrhotic rats with CCl4-induced portal hypertension.
Le texte complet de cet article est disponible en PDF.Plan
Vol 41 - N° 3
P. 303-310 - juin 2017 Retour au numéro
Article précédent
- Mutations in basal core promoter is associated with significant fibrosis in both HBeAg positive and negative treatment-naïve chronic hepatitis B
- Li-Bo Yan, Xia Zhu, Lang Bai, Xiao-Qiong Tang, Ling-Yao Du, En-Qiang Chen, Ling-Bo Liang, Hong Tang
- The development of hepatocarcinoma after long-term antivirus treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes and predictive factors
- Zhi-Qin Li, Chun-Ling Hu, Ping Yu, Xin-Yu Gu, Jia-Jia Zhang, Hua Li, Hong-Yu Zhang, Jun Lv, Yan-Min Liu, Qing-Lei Zeng, Jing-Ya Yan, Zu-Jiang Yu, Yi Zhang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?